NDA 018708 · Galt Pharms
Doral
Quazepam · Oral · Benzodiazepine
NovelLast checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 27, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
302
274 serious, 47 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7 )] . The use of benzodiazepines, including Quazepam Tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...
What it is approved for
From the label in effect Oct 23, 2025.
Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. Quazepam Tablets, a gamma-aminobutyric (GABAA) agonist, is indicated for the treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. ( 1 )
Mechanism: Quazepam Tablet, like other central nervous system agents of the 14-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 27, 1985 Original approval · Type 1 - New Molecular Entity ReviewOther Important Information from FDA
2 products under this application
- DORAL · QUAZEPAM 7.5MG · TABLET, ORAL · Discontinued
- DORAL · QUAZEPAM 15MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Quazepam" as an intervention, any sponsor and status, largest first.
Minamihanno HospitalAcademic, hospital or other
NCT00707915 · 30 participants · Start Jan 2008 · Primary completion Jul 2010
Drug: Drug: Benzodiazepine (listed out below) · For: Adverse Effects
Sites: Hannou, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- suicide attempt27
- altered state of consciousness26
- intentional overdose25
- hypoglycaemia18
- completed suicide17
- pyrexia16
- overdose15
- somnolence15
- delirium13
- fall13
- nausea13
- blood creatine phosphokinase increased12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 7 |
| 2006 | 11 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 18 |
| 2012 | 14 |
| 2013 | 15 |
| 2014 | 15 |
| 2015 | 41 |
| 2016 | 22 |
| 2017 | 29 |
| 2018 | 37 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 13 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Quazepam versus triazolam in patients with sleep disorders: a double-blind study.
Mauri MC, Gianetti S, Pugnetti L, et al. · Int J Clin Pharmacol Res 1993 · Clinical Trial, Comparative Study
- Short-term quazepam treatment of insomnia in geriatric patients.
Caldwell JR · Pharmatherapeutica 1982 · Clinical Trial, Randomized Controlled Trial
- Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy.
Zheng X, He Y, Yin F, et al. · Sleep Med 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam.
Nishiyama T, Yamashita K, Yokoyama T, et al. · J Anesth 2007 · Comparative Study, Randomized Controlled Trial
- Short-term study of quazepam 15 milligrams in the treatment of insomnia.
Hernández Lara R, Del Rosal PL, Ponce MC · J Int Med Res 1983 · Clinical Trial, Randomized Controlled Trial
Sponsor: Galt Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.